Building a Better Cell Therapy CDMO

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Pharma's Almanac

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Pharma's Almanac

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

HACs

Synthetic Chromosome Therapeutics: Expanding Genomic Medicine Beyond the Limits of Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

CRISPR vs. Base Editing vs. Prime Editing: Which Genome Editing Technology Is Best?

Pharma's Almanac

Pathfinder

NK Cell Therapy vs. T Cell Therapy: Which Cell Therapy Platform Is Better for Cancer Treatment?

Pharma's Almanac

Pathfinder

AAV vs. Non-Viral Gene Delivery: Which Is Better for In Vivo Gene Therapy?

Pharma's Almanac